CŌRE Diagnostics, a clinical laboratory specialising in next-generation diagnostics, has partnered with Digistain to launch the UK's pioneering Breast Cancer Risk Profiling Technology in India, Nepal, Bhutan, and Bangladesh.
The company in a press statement said that Digistain stands out as a digital solution endorsed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) offering rapid, AI-enabled insights into cancer grading and prognosis, aiding in predicting breast cancer recurrence post-surgery. This innovation aims to spare breast cancer patients from unnecessary chemotherapy, promising a more targeted and efficient treatment approach.
Developed with the collaboration of over 1,500 oncologists and extensively trialled at esteemed cancer centres like Nottingham University NHS Trust and Cancer Research UK, Digistain has garnered approval from the National Health Service (NHS).
Dr Hemmel Amrania PhD, CEO of Digistain, spearheaded the development of this groundbreaking technology. His extensive background in clinical science from Imperial College and Université Paris XI culminated in a novel diagnostic method recognised with the prestigious President’s Award for Outstanding Research. Dr. Amrania's expertise promises to drive significant advancements in cancer prognosis and treatment outcomes.
“This partnership marks a monumental stride in the battle against breast cancer, offering a faster, more accurate, and cost-effective approach to cancer prognosis and treatment. CŌRE Diagnostics and Digistain are dedicated to enhancing patient outcomes and reshaping the healthcare landscape,” commented Dinesh Chauhan, CEO of CŌRE Diagnostics
_20240702152420_original_image_10.webp)
_20240702142212_original_image_28.webp)
_20240701194857_original_image_40.webp)
